We are live on ! Find out more
DRUG

Bright Minds Biosciences
DRUG

94 hedge funds and large institutions have $670M invested in Bright Minds Biosciences in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 45 increasing their positions, 15 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

314% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 7

200% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 15

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

30% more capital invested

Capital invested by funds: $515M → $670M (+$155M)

27% more funds holding

Funds holding: 74 → 94 (+20)

9.77% more ownership

Funds ownership: 84.64% → 94.41% (+9.8%)

Holders
94
Holders Change
+20
Holders Change %
+27.03%
% of All Funds
1.16%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
29
Increased
45
Reduced
15
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VPC
Vestal Point Capital
New York
+$39.6M
2
DM
Deerfield Management
New York
+$22.8M
3
RCM
RA Capital Management
Massachusetts
+$21.3M
4
BlackRock
BlackRock
New York
+$18.3M
5
GPP
Great Point Partners
Connecticut
+$17.7M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$11.4M
2
SC
Stempoint Capital
New York
-$7.6M
3
PA
Perceptive Advisors
New York
-$5.78M
4
SCM
Superstring Capital Management
New York
-$2.73M
5
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$1.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
VPM
26
Vanguard Portfolio Management
Pennsylvania
$4.41M +$4.87M +60,482 New
Walleye Capital
27
Walleye Capital
New York
$3.92M +$2.24M +27,880 +108%
Millennium Management
28
Millennium Management
New York
$3.86M -$11.4M -141,605 -73%
BFM
29
Boothbay Fund Management
New York
$3.74M +$306K +3,800 +8%
Ameriprise
30
Ameriprise
Minnesota
$3.65M +$4.03M +50,027 New
WP
31
Woodline Partners
California
$3.33M +$3.68M +45,668 New
PHP
32
Parkman Healthcare Partners
Connecticut
$2.93M +$3.23M +40,098 New
O
33
OrbiMed
New York
$2.92M +$3.22M +40,000 New
AGP
34
Artia Global Partners
Florida
$2.8M +$402K +5,000 +15%
Northern Trust
35
Northern Trust
Illinois
$2.73M +$950K +11,808 +46%
ACM
36
ADAR1 Capital Management
Texas
$2.47M +$2.45M +30,400 +869%
KCA
37
KVP Capital Advisors
California
$2.32M +$2.56M +31,813 New
Bank of America
38
Bank of America
North Carolina
$1.42M +$350K +4,347 +29%
PIM
39
Platinum Investment Management
Australia
$1.4M -$210K -2,603 -12%
D.E. Shaw & Co
40
D.E. Shaw & Co
New York
$1.13M +$928K +11,528 +294%
Charles Schwab
41
Charles Schwab
California
$1.12M +$230K +2,853 +23%
SCM
42
Superstring Capital Management
New York
$971K -$2.73M -33,967 -72%
UBS Group
43
UBS Group
Switzerland
$969K -$42.9K -533 -4%
Bank of New York Mellon
44
Bank of New York Mellon
New York
$967K +$263K +3,264 +33%
SSA
45
Schonfeld Strategic Advisors
New York
$966K -$1.37M -16,967 -56%
AI
46
AdvisorShares Investments
Maryland
$920K +$215K +2,669 +27%
SEI Investments
47
SEI Investments
Pennsylvania
$816K +$901K +11,188 New
GCM
48
Ghisallo Capital Management
Massachusetts
$803K +$885K +11,000 New
EI
49
EAM Investors
California
$671K +$740K +9,189 New
N
50
Nuveen
North Carolina
$608K +$189K +2,342 +39%
1
2
3 4 5

DRUG Hedge Fund Activity: Q1 2026 in Review

94 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Bright Minds Biosciences (DRUG) for Q1 2026, worth a combined $670M — up 30% from $515M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new DRUG positions and 7 closed out — a net gain of 22 holders — while 45 added to existing stakes and 15 trimmed.

The largest buyer was Vestal Point Capital, opening a new position worth an estimated $39.6M. The largest seller was Millennium Management, cutting an estimated $11.4M.

  • 94 institutional investors held Bright Minds Biosciences (DRUG) as of Q1 2026, up from 74 in Q4 2025.
  • Funds reported $670M of Bright Minds Biosciences stock for Q1 2026, up 30% quarter-over-quarter.
  • 29 funds opened new Bright Minds Biosciences positions in Q1 2026 and 7 closed out, a net change of +22 holders.
  • The largest Bright Minds Biosciences buyer in Q1 2026 was Vestal Point Capital, an estimated $39.6M added.
  • The largest Bright Minds Biosciences seller in Q1 2026 was Millennium Management, an estimated $11.4M sold.

Based on aggregated 13F filings for Q1 2026.